Effect of ganglioside combined with pramexol in the treatment of Parkinson's disease and its effect on motor function
Ganglioside combined with pramexol for Parkinson's disease
Abstract
Background: This study was aimed to evaluate the efficacy of pramipexole combined with ganglioside for PD treatment and pramipexole monotherapy, so as to provide reference for clinical practice.
Methods: 61 PD patients selected from June 2019 to December 2020 at our hospital were divided into two groups. The control group (n=31) was given dopasizide oral treatment, and the treatment group (n=30) was given ganglioside combined with pramipexole. The clinical efficacy, adverse reactions, motor function scores, UPDRS scores, PDQ-39 scale scores, TNF-α levels, and related serum factor levels were measured.
Results: Compared with control group, the total effective rate was obviously increased. The CRP and TNF–α levels, the speech tone and speed, sitting and walking posture, writing and hands ability scores were reduced, while the BDNF level was increased in treatment group. During the period, compared with the control group, the incidence of adverse reactions in the treatment group was significantly decreased.
Conclusions: Ganglioside combined with pramipexole was effective in treating PD. It can effectively reduce the level of CRP and TNF-α, increase the level of BDNF, improve neurological function, improve motor function, and does not increase the adverse reactions of patients. It is worthy of application.
References
1. Zhao H, Ning Y, Cooper J, Refoios CR, Ni X, Yi B, et al. Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-Analysis. Adv Ther 2019; 36(6): 1252-1265.
2. Postuma RB, Gagnon JF, Bertrand JA, Genier MD, Montplaisir JY. Parkinson risk in idiopathic REM sleep behavior disorder: preparing for neuroprotective trials. Neurology 2015; 84(11): 1104-1113.
3. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, et al. Parkinson disease. Nat Rev Dis Primers 2017; 3: 17013.
4. Hirsch L, Jette N, Frolkis A, Steeves T, Pringsheim T. The Incidence of Parkinson's Disease: A Systematic Review and Meta-Analysis. Neuroepidemiology 2016; 46(4): 292-300.
5. Zhao H, Ning Y, Cooper J, Refoios CR, Ni X, Yi B, et al. Indirect Comparison of Ropinirole and Pramipexole as Levodopa Adjunctive Therapy in Advanced Parkinson's Disease: A Systematic Review and Network Meta-Analysis . Adv Ther 2019; 36(6): 1252-1265.
6. Zhou H, Li S, Yu H, Sun S, Wan X, Zhu X, et al. Efficacy and Safety of Pramipexole Sustained Release versus Immediate Release Formulation for Nocturnal Symptoms in Chinese Patients with Advanced Parkinson's Disease: A Pilot Study. Parkinsons Dis-Us 2021; 2021: 8834950.
7. Wang Y, Sun SG, Zhu SQ, Liu CF, Liu YM, Di Q, et al. Analysis of pramipexole dose-response relationships in Parkinson's disease. Drug Des Devel Ther 2017; 11:83-89.
8. Utsumi H, Okuma Y, Kano O, Suzuki Y, Iijima M, Tomimitsu H, et al. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease. Internal Med 2013; 52(3): 325-332.
9. Jiang DQ, Jiang LL, Wang Y, Li MX. The role of pramipexole in the treatment of patients with depression and Parkinson's disease: A meta-analysis of randomized controlled trials. Asian J Psychiatr 2021; 61:102691.
10. Antonini A, Barone P, Ceravolo R, Fabbrini G, Tinazzi M, Abbruzzese G. Role of pramipexole in the management of Parkinson's disease. Cns Drugs 2010; 24(10): 829-841.
11. Smith JA, Das A, Ray SK, Banik NL. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull 2012; 87(1): 10-20.
12. Wang Q, Liu Y, Zhou J. Neuroinflammation in Parkinson's disease and its potential as therapeutic target. Transl Neurodegener 2015; 4: 19.
13. Guo YL, Duan WJ, Lu DH, Ma XH, Li XX, Li Z, et al. Autophagy-dependent removal of alpha-synuclein: a novel mechanism of GM1 ganglioside neuroprotection against Parkinson's disease. Acta Pharmacol Sin 2021; 42(4): 518-528.
14. Sipione S, Monyror J, Galleguillos D, Steinberg N, Kadam V. Gangliosides in the Brain: Physiology, Pathophysiology and Therapeutic Applications. Front Neurosci-Switz 2020; 14: 572965.
15. Schneider JS, Cambi F, Gollomp SM, Kuwabara H, Brasic JR, Leiby B, et al. GM1 ganglioside in Parkinson's disease: Pilot study of effects on dopamine transporter binding. J Neurol Sci 2015; 356(1-2): 118-123.
16. Yahi N, Di Scala C, Chahinian H, Fantini J. Innovative treatment targeting gangliosides aimed at blocking the formation of neurotoxic alpha-synuclein oligomers in Parkinson's disease. Glycoconjugate J 2022; 39(1): 1-11.
17. Itokazu Y, Fuchigami T, Morgan JC, et al. Intranasal infusion of GD3 and GM1 gangliosides downregulates alpha-synuclein and controls tyrosine hydroxylase gene in a PD model mouse. Mol Ther, 2021, 29 (10): 3059-3071.
18. Schneider JS, Aras R, Williams CK, Koprich JB, Brotchie JM, Singh V. GM1 Ganglioside Modifies alpha-Synuclein Toxicity and is Neuroprotective in a Rat alpha-Synuclein Model of Parkinson's Disease. Sci Rep-Uk 2019; 9(1): 8362.
19. Wu G, Lu ZH, Seo JH, Alselehdar SK, DeFrees S, Ledeen RW. Mice deficient in GM1 manifest both motor and non-motor symptoms of Parkinson's disease; successful treatment with synthetic GM1 ganglioside. Exp Neurol 2020; 329: 113284.
20. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Movement Disord 2008; 23(15): 2129-2170.
21. Katsarou Z, Bostantjopoulou S, Peto V, Alevriadou A, Kiosseoglou G. Quality of life in Parkinson's disease: Greek translation and validation of the Parkinson's disease questionnaire (PDQ-39). Qual Life Res 2001; 10(2): 159-163.
22. Jiang DQ, Zang QM, Jiang LL, Wang Y, Li MX, Qiao JY. Comparison of pramipexole and levodopa/benserazide combination therapy versus levodopa/benserazide monotherapy in the treatment of Parkinson's disease: a systematic review and meta-analysis. N-S Arch Pharmacol 2021; 394(9): 1893-905.
23. Pagano G, Niccolini F, Wilson H, Yousaf T, Khan NL, Martino D, et al. Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease. Movement Disord 2019; 34(10): 1505-1515.
24. Deleidi M, Gasser T. The role of inflammation in sporadic and familial Parkinson's disease. Cell Mol Life Sci 2013; 70(22): 4259-4273.
25. Muller SK, Bender A, Laub C, Hogen T, Schlaudraff F, Liss B, et al. Lewy body pathology is associated with mitochondrial DNA damage in Parkinson's disease. Neurobiol Aging 2013; 34(9): 2231-2233.
26. Mcgeer PL, Itagaki S, Boyes BE, et al. Reactive microglia are positive for HLA-DR in the substantion nigra of Parkinson's and Alzheimer's disease brains. Neurology, 1988, 38(8): 1285-1291.
27. Tyagi RK, Bisht R, Pant J, Kumar P, Majeed AB, Prakash A. Possible role of GABA-B receptor modulation in MPTP induced Parkinson's disease in rats. Exp Toxicol Pathol 2015; 67(2): 211-217.
28. Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosur Ps 1999; 66(4): 436-41.
29. Farbood Y, Sarkaki A, Dolatshahi M, Taqhi MS, Khodadadi A. Ellagic Acid Protects the Brain Against 6-Hydroxydopamine Induced Neuroinflammation in a Rat Model of Parkinson's Disease. Basic Clin Neurosci 2015; 6(2): 83-89.
30. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem be 1997; 56(1): 131-137.
31. Kottgen A, Selvin E, Stevens LA, Levey AS, Van Lente F, Coresh J. Serum cystatin C in the United States: the Third National Health and Nutrition Examination Survey (NHANES III). Am J Kidney Dis 2008; 51(3): 385-394.
32. Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson's disease. Movement Disord 2011; 26(6): 1049-1055.
33. Oster S, Radad K, Scheller D, Hesse M, Balanzew W, Reichmann H, et al. Rotigotine protects against glutamate toxicity in primary dopaminergic cell culture. Eur J Pharmacol 2014; 724: 31-42.
34. Koutsilieri E, Riederer P. Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease. Parkinsonism Relat D 2007; 13 Suppl 3: S329-331.
Copyright (c) 2023 Xinna Li, Peihai Han, Mengjiao Liu, Xiaowen Li, Shuai Xue
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.